EPIDEMIOLOGY AND PREVENTION OF MEASLES: CURRENT ISSUES


Cite item

Full Text

Abstract

There are presented data characterizing measles (ICD-10 B05) as the most contagious viral infection, its contagiousness is more than 90%. RNA virus of the genus morbilliviruses of the paramyxovirus family is the causative agent of measles. The incidence of measles is recorded among children and among adults, mainly among unvaccinated against this infection. The source of infection is only a measles-sick person, who is dangerous to others already 3-5 days before the rash appears. The features of the epidemic process of measles in connection with immunization and the gain in collective immunity are described. From 2012 to the present, the measles epidemic situation has been shown to be complicated, which has been the reason for the repeated postponement of the deadlines for its liquidation, proclaimed by WHO. Sufficient conditions for achieving the elimination of measles are formulated. First of all, it is necessary to maintain a 95% level of immunity in the prescribed age and professional groups of the population.

About the authors

Galina I. Smirnova

I.M. Sechenov First Moscow State Medical University

Email: gismirnova@yandex.ru
MD, Ph.D., DSci., Professor, Honored Doctor of the Russian Federation, Professor of the Department of Pediatrics and Pediatric Infectious Diseases Moscow, Trubetskaya str., 8/2, 119121, Russian Federation

A. A Korsunskiy

I.M. Sechenov First Moscow State Medical University

доктор мед. наук, проф., зав. каф. педиатрии и детских инфекционных болезней Сеченовского университета; гл. врач ДГКБ № 9 Департамента здравоохранения Москвы. Moscow, Trubetskaya str., 8/2, 119121, Russian Federation

References

  1. Титова Н.С. Корь: история, настоящее, перспектива. Эпидемиология и вакцинопрофилактика. 2002; 2: 9-16.
  2. Moss WJ. Measles. Lancet. 2017; 390(10111): 2490-502. doi: 10.1016/S0140-6736(17)31463-0.
  3. Girmay A, Dadi AF. Being unvaccinated and having a contact history increased the risk of measles infection during an outbreak: a finding from measles outbreak investigation in rural district of Ethiopia. BMC Infect Dis. 2019; 19(1): 345. doi: 10.1186/s12879-019-3973-8.
  4. Онищенко Г.Г., Попова А.Ю., Алешкин В.А., ред. Корь в России: проблемы ликвидации. М.; Династия; 2017.
  5. Muscat M. Who gets measles in Europe? J Infect Dis. 2011; 204(Suppl 1): 353-65. doi: 10.1093/infdis/jir067.
  6. Schoini P, Karampitsakos T, Avdikou M, Athanasopoulou A, Tsoukalas G, Tzouvelekis A. Measles Pneumonitis. Adv Respir Med. 2019. doi: 10.5603/ARM.a2019.0010.
  7. Артемова И.А., Куличенко Т.В. Эпидемия кори. Реальна ли угроза? Вопросы современной педиатрии. 2017; 16(5): 358-61.
  8. Цвиркун, О.В., Герасимова A.Г., Садыкова Д.К. Роль единой системы надзора за корью и краснухой в период элиминации кори. Эпидемиология и вакцинопрофилактика.2003; 2: 16-7.
  9. De Serres G, Gay NJ, Farrington CP. Epidemiology of transmissible diseases after elimination. Am J Epidemiol. 2000; 151(11): 1039-48. doi: 10.1093/infdis/jir083.
  10. Onishchenko G, Ezhlova E, Gerasimova A, Tsvirkun O, Shulga S, Lipskaya G et al. Progress toward measles elimination in the Russian Federation, 2003-2009. J Infect Dis. 2011; 204 (Suppl 1): 366-72. doi: 10.1093/infdis/jir083.
  11. Покровский В.И., Брико Н.И. Общая эпидемиология с основами доказательной медицины. 2-е изд. М.; ГЭОТАР-Медиа, 2012.
  12. Цвиркун О.В., Герасимова A.Г., Тихонова Н.Т. Особенности распространения и формирования очагов кори в период элиминации. Здоровье населения и среда обитания. 2009; 3: 19-25.
  13. Бектимиров Т.А. Успехи вакцинопрофилактики, кори, краснухи и эпидемического паротита за рубежом. Вакцинация. 2006; 4(46): 4-5.
  14. Christi A.S., Gay A. The measles initiative: moving toward measles eradication. J Infect Dis. 2011; 204(Suppl 1): 14-17.
  15. Цвиркун О.В., Лыткина И.Н., Ежлова Е.Б., Тихонова Н.Т., Герасимова A.Г., Тураева Н.В. Влияние специфической профилактики против кори на уровень и структуру годовой заболеваемости в Российской Федерации. Инфекционные болезни. 2011; 9(1): 23-7.
  16. Герасимова А.Г., Цвиркун О.В., Тихонова Н.Т., Чава О.О. Эпидемиологический надзор за корью в период элиминации. Эпидемиология и вакцинопрофилактика. 2008; 4(41): 8-12.
  17. Цвиркун, О.В., Герасимова A.Г., Тихонова Н.Т., Тураева Н.В., Пименова А.С. Структура заболевших корью в период элиминации. Эпидемиология и вакцинопрофилактика. 2012; 2(63): 21-6.
  18. Perry RT, Gacic-Dobo M, Dabbagh A, Mulders MN, Strebel PM, Okwo-Bele JM et al. Global control and regional elimination of measles, 2000-2012. MMWR Morb Mortal Wkly Rep. 2014; 63(5): 103-7.
  19. Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16-17 March 2000. J Infect Dis. 2004; 189(Suppl 1): 43-7.
  20. Levin A., Burgess C., Garrison L. Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis. 2011; 204(Suppl 1): 98-106.
  21. Sundell N, Dotevall L, Sansone M, Andersson M, Lindh M, Wahlberg T et al. Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: low viral load in breakthrough infections. Euro Surveill. 2019; 24(17). doi: 10.2807/1560-7917.ES.2019.24.17.1900114.
  22. Bitzegeio J, Majowicz S, Matysiak-Klose D, Sagebiel D, Werber D. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity. Euro Surveill. 2019; 24(17). doi: 10.2807/1560-7917. ES.2019.24.17.1800529.
  23. Zimmerman LA, Muscat M, Singh S, Ben Mamou M, Jankovic D, Datta S et al. Progress Toward Measles Elimination - European Region, 2009-2018. MMWR Morb Mortal Wkly Rep. 2019; 68(17): 396-401. doi: 10.15585/mmwr.mm6817e1.
  24. Dascalu S. Measles Epidemics in Romania: Lessons for Public Health and Future Policy. Front Public Health. 2019;7:98. doi: 10.3389/fpubh.2019.00098.
  25. Ноздрачева А.В., Семененко Т.А., Асатрян М.Н., Шмыр И.С., Ершов И.Ф., Соловьев Д.В. и соавт. Иммунологическая восприимчивость населения мегаполиса к кори на этапе ее элиминации. Эпидемиология и вакцинопрофилактика. 2019; 18(1): 18-26. doi: 10.31631/2073-3046-2019-18-2-18-26.
  26. Hopkins Tanne J. Measles: two US outbreaks are blamed on low vaccination rates. BMJ. 2019; 364: l312. doi: 10.1136/bmj.l312. doi: 10.4103/jfmpc.jfmpc_234_18.
  27. Nelson R. US measles outbreak concentrated among unvaccinated children. Lancet Infect Dis. 2019; 19(3): 248. doi: 10.1016/S1473-3099(19)30074-X.
  28. Patel M, Lee AD, Redd SB, Clemmons NS, McNall RJ, Cohn AC, Gastañaduy PA. Increase in Measles Cases - United States, January 1-April 26, 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(17): 402-4.
  29. Mankertz A., Mulders M.,Shulga S. Molecular genotyping and epidemiology of measles virus transmission in the World Health Organization European Region, 2007-2009. J Infect Dis. 2011; 204(Suppl 1): 335-42.
  30. Smiianov VA, Zaitseva HS, Kurganskaya VA, Dyachenko AG, Zbarazhskyi VP, Smiianov YV, Pilipec OA. Vaccination coverage rates and the incidence of vaccine preventable diseases among children in sumy region of Ukraine. Wiad Lek. 2019; 72(2): 255-60.
  31. Measles vaccines: WHO position paper. Wkly Epidemiol Rec. 2017; 92(17): 205-27.
  32. Dabbagh A, Patel MK, Dumolard L, Gacic-Dobo M, Mulders MN, Okwo-Bele JM et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2016. MMWR Morb Mortal Wkly Rep. 2017; 66(42): 1148-53. doi: 10.1016/j.vaccine.2017.10.065.
  33. Tunis MC, Salvadori MI, Dubey V, Baclic O. Updated NACI recommendations for measles post-exposure prophylaxis. Can Commun Dis Rep. 2018; 44(9): 226-30. doi: 10.14745/ccdr.v44i09a07.
  34. Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis. 2017; 65(11): 1843-7. doi: 10.1093/cid/cix639
  35. O’Donnell S, Davies F, Vardhan M, Nee P. Could this be measles? Emerg Med J. 2019; 36(5): 310-4. doi: 10.1136/emermed-2019-208490.
  36. Lee CT, Hagan JE, Jantsansengee B, Tumurbaatar OE, Altanchimeg S, Yadamsuren B et al. Increase in Infant Measles Deaths during a Nationwide Measles Outbreak - Mongolia, 2015-2016. J Infect Dis. 2019. doi: 10.1093/infdis/jiz140.
  37. Kriss JL, Grant GB, Moss WJ, Durrheim DN, Shefer A, Rota PA et al. Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey. Vaccine. 2019. doi: 10.1016/j.vaccine.2019.02.058.
  38. Таточенко В.К., Озерковский Н.А., Федоров А.М. Иммунопрофилактика-2014. Справочник. М.: ПедиатрЪ; 2014.
  39. Noori N, Rohani P. Quantifying the consequences of measles-induced immune modulation for whooping cough epidemiology. Philos Trans R Soc Lond B Biol Sci. 2019; 374(1775): 20180270. doi: 10.1098/rstb.2018.0270.
  40. Moss, W.J., Strebel P. Biological feasibility of measles eradication. J Infect Dis. 2011; 204(Suppl 1): 47-53. doi: 10.1093/infdis/jir065.
  41. Keegan R., Dabbagh A, Strebel P., Cochi S. Comparing measles with previous eradication programs: enabling and constraining factors. J Infect Dis. 2011; 204(Suppl 1): 54-61.
  42. Haralambieva IH, Kennedy RB, Ovsyannikova IG, Schaid DJ, Poland GA. Current perspectives in assessing humoral immunity after measles vaccination. Expert Rev Vaccines. 2019; 18(1): 75-87. doi: 10.1080/14760584.2019.1559063.
  43. Truelove SA, Graham M, Moss WJ, Metcalf CJE, Ferrari MJ, Lessler J. Characterizing the impact of spatial clustering of susceptibility for measles elimination. Vaccine. 2019; 37(5): 732-41. doi: 10.1016/j.vaccine.2018.12.012.

Copyright (c) 2019 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies